Identifying biologically-based predictors and mechanisms related to the development of psychosis is critical to early detection and disability prevention efforts. The multi-site North American Prodrome Longitudinal Study combined baseline neurobiological assessment with longitudinal clinical follow-up of adolescents and young adults identified as clinical high risk (CHR) for developing psychosis. This session will present data on electrophysiology studies from the NAPLS 2 cohort with a focus on highlighting baseline electrophysiological markers that relate to 24-month clinical outcomes including, but not limited to, transition to psychotic spectrum disorders. Dr. Fryer from the University of California, San Francisco (UCSF) will present data from the mismatch negativity (MMN) paradigm, focusing on the relationship between measures of predictive coding at baseline and clinical outcomes 24 months later. Dr. Carrión from Hofstra Northwell School of Medicine will present a study on the functional impact of these MMN deficits by discussing interrelationships among MMN, negative symptoms, and cognitive and social functioning. Dr. Guillory from the Ichan School of Medicine at Mount Sinai will present a study comparing MMN and P300 functioning in CHR individuals with and without comorbid autism spectrum diagnoses including the extent to which this comorbidity influences biomarker relationships to conversion status. Dr. Niznikiewicz from Harvard Medical School will present findings on the gamma-band auditory steady-state response in youth at CHR for psychosis compared to healthy controls and conversion-based analyses within CHR. Dr. Mathalon from UCSF is the electrophysiology lead for NAPLS and will serve as the session’s discussant.
